Table of Contents - Espicom

DIABETES LANDSCAPE 

Market, Technology and 

Intellectual Property 

May 2012 

A Joint Research Report from 

Espicom and UBM TechInsights.

This report is the result of a collaborative venture between UBM TechInsights and Espicom Business Intelligence, 

each party bringing its own skills and knowledge to provide an unmatched analysis. 

UBM TechInsights 

UBM TechInsights is the leading provider of sophisticated information and advice to technology firms. 

Companies in need of technical analysis and IP management consulting rely on our deep expertise in the underlying technologies used 

in today’s medical devices. 

For further information: 

www.ubmtechinsights.com/medical 

Espicom Business Intelligence 

Espicom is a highly-regarded and established independent provider of business intelligence services for the global medtech industries. 

Based in the UK and with over 30 years of continuous research and editorial experience in the global health industry, Espicom is one of 

the longest established, independent business intelligence providers operating today. 

Espicom produces original analysis, news and forecasts using its skilled and experienced team of full-time in-house analysts, researchers and 

editorial experts. Over 50,000 users in more than 50 countries worldwide rely on Espicom’s essential market data. 

For further information: 

www.espicom.com/medical 

Diabetes Landscape: Market, Technology and Intellectual Property 

May 2012 

© Copyright 2012 Espicom Business Intelligence 

© 2012, UBM Semiconductor Insights 

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or 

mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of 

the publisher. 

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for 

decisions made on the basis of information contained herein. 

ii © Espicom Business Intelligence © 2012 UBM Semiconductor Insights 

May 2012

Diabetes Landscape: 

CONTENTS 

Table of Contents 

EXECUTIVE SUMMARY 

Volume I ................................................................................................................................................................................... 1 

Current Technologies ............................................................................................................................................................................... 2 

Geographic Trends .................................................................................................................................................................................... 2 

Volume II .................................................................................................................................................................................. 2 

Intellectual Property Trends ................................................................................................................................................................... 3 

Technology Trends .................................................................................................................................................................................... 3 

VOLUME I - DIABETES INDUSTRY ANALYSIS 

1.0 MARKET OVERVIEW .....................................................................................................................................7 

1.1 BACKGROUND ............................................................................................................................................................................7 

1.1.1 Diagnosis and Management of Diabetes ..................................................................................................................... 8 

Insulin-Dependant Diabetes Patients ................................................................................................................................................... 9 

Current Trends in Diabetes Care ............................................................................................................................................................. 9 

1.2 THE GLOBAL DIABETES BURDEN ...........................................................................................................................................10 

1.2.1 Diabetes Prevalence .................................................................................................................................................... 10 

Fig.1.0: Diabetes Prevalence by Geographic Region, 2011-2030 ...................................................................................................................................................................11 

Diabetes Prevalence for the Top 10 Countries, 2011-2030 (million) ..............................................................................................................................................................11 

Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group Study ................................................................... 12 

1.2.2 Mortality ...................................................................................................................................................................... 12 

1.2.3 Diabetes Complications ............................................................................................................................................. 13 

1.2.4 The Cost of Diabetes .................................................................................................................................................... 14 

1.3 THE DIABETES DEVICE MARKET ............................................................................................................................................15 

1.3.1 Product Segments ....................................................................................................................................................... 16 

Fig.1.2: Diabetes Device Market by Major Product Category, 2011 ...............................................................................................................................................................16 

Fig.1.3: Percentage of US Diabetes Patients by Treatment Type, 2007-2009 ................................................................................................................................................17 

Fig.1.4: Diabetes Device Market by Product Type, 2011 .................................................................................................................................................................................18 

1.3.2 Current Market Trends ............................................................................................................................................... 19 

Fig.1.5: Global Diabetes Device Market, 2011 (US$ billion) ...........................................................................................................................................................................19 

Global Diabetes Market by Product Type, 2005-2011 (US$ million) .............................................................................................................................................................20 

Fig.1.6: Global Diabetes Market By Product Type, 2005-2011 (US$ billion) ..................................................................................................................................................20 

Global Diabetes Market Growth Rates by Product Type, 2006-2011 (%) .....................................................................................................................................................21 

Fig.1.7: Global Diabetes Device Market Growth Rates, 2006-2011 (%) ........................................................................................................................................................21 

1.3.3 Regional Perspective .................................................................................................................................................. 21 

Fig.1.8: Global Diabetes Device Market by Region, 2011 ...............................................................................................................................................................................22 

Fig.1.9: US Market by Product Type, 2011 ......................................................................................................................................................................................................22 

Fig.1.10: European Market by Product Type, 2011 ........................................................................................................................................................................................23 

Fig.1.11: Other Regions by Product Type, 2011 ..............................................................................................................................................................................................23 

1.4 COMPETITIVE ENVIRONMENT ...............................................................................................................................................24 

Fig.1.12: Diabetes Device Market Share by Company, 2011 ...........................................................................................................................................................................25 

Key Companies’ Diabetes Care Sales, 2005-2011 (US$ million) ....................................................................................................................................................................25 

Non-US Companies’ Diabetes Sales in Reported Currency, 2005-2011 (million) ..........................................................................................................................................25 

Leading Companies’ International Diabetes Care Sales, 2005-2011 (US$ million) .......................................................................................................................................26 

Leading Companies’ US Diabetes Care Sales, 2005-2011 (US$ million) ........................................................................................................................................................26 

1.4.1 New Market Entrants ...................................................................................................................................................26 

1.4.2 Market Withdrawals .................................................................................................................................................... 27 

1.4.3 Rounding Out Product Portfolios ..............................................................................................................................28 

Key Companies: Market Presence & Position by Product Area ......................................................................................................................................................................28 

Key Companies: Current & Future Potential Market Presence by Product Area ............................................................................................................................................29 

1.4.4 Market Consolidation .................................................................................................................................................29 

1.5 GROWTH DRIVERS, RESTRAINTS AND FUTURE OPPORTUNITIES ....................................................................................30 

1.5.1 Regulatory and Reimbursement Environment ........................................................................................................ 31 

May 2012 

© Espicom Business Intelligence © 2012 UBM Semiconductor Insights 

iii


iv 



1.5.2 Connectivity and Data Integration ............................................................................................................................32 

The Role of Telemonitoring in Diabetes Care ....................................................................................................................................32 

Safety Issues .............................................................................................................................................................................................33 

1.5.3 Emerging Technologies ..............................................................................................................................................34 

New-Generation Insulin Delivery Devices ......................................................................................................................................... 34 

Development of a Closed-Loop System ..............................................................................................................................................35 

Rival Technologies ..................................................................................................................................................................................35 

1.6 MARKET EXPECTATIONS ........................................................................................................................................................ 38 

Fig.1.13: Global Diabetes Device Market, 2011-2017E (US$ billion) ..............................................................................................................................................................38 

Global Diabetes Market Forecast by Product Type, 2011-2017E (US$ million) ............................................................................................................................................. 39 

Global Diabetes Market Forecast Growth Rates by Product, 2011-2017E (%) ............................................................................................................................................. 39 

Fig.1.14: Global Monitoring Market Forecast, 2011-2017E (US$ billion) ....................................................................................................................................................... 39 

Fig.1.15: Global Insulin Delivery Market Forecast, 2011-2017(E) (US$ billion) .............................................................................................................................................40 

Fig.1.16: Diabetes Device Market by Product, 2017E ....................................................................................................................................................................................40 

2.0 DIABETES MONITORING PRODUCTS .......................................................................................................41 

Overview: Glucose Monitoring Products ...........................................................................................................................42 

2.1 MARKET DYNAMICS ............................................................................................................................................................... 44 

Fig.2.1: Global Glucose Monitoring Market, 2005-2011 (US$ billion)...........................................................................................................................................................44 

Fig.2.2: Global Blood Monitoring Market Growth, 2005-2011 (%) .............................................................................................................................................................44 

Fig.2.3: Glucose Monitoring Market by Product Type, 2011 ......................................................................................................................................................................... 45 

Fig.2.4: Blood Glucose Testing Market by Geographic Region, 2011 ............................................................................................................................................................ 45 

Public Companies’ Glucose Monitoring Sales, 2005-2011 (US$ million) ...................................................................................................................................................... 45 

Fig.2.5: Glucose Monitoring Market Shares by Company, 2011 ...................................................................................................................................................................46 

2.2 MANUAL SELF-MONITORING BLOOD GLUCOSE PRODUCTS .......................................................................................... 47 

Fig.2.6: Example of a Classic BGM & Test Strip: Bayer’s Contour Meter .......................................................................................................................................................48 

2.2.1 Current Market Environment .................................................................................................................................... 48 

Fig.2.7: Global SMBG Market, 2005-2011 (US$ million) ...............................................................................................................................................................................49 

Fig.2.8: Global SMBG Market Growth Rates, 2005-2011 (%) ......................................................................................................................................................................49 

Fig.2.9: SMBG Market by Product Type, 2011 ...............................................................................................................................................................................................49 

Regional Markets and Reimbursement ............................................................................................................................................. 50 

Fig.2.10: SMBG Market by Region, 2011 .......................................................................................................................................................................................................50 

Market Developments ............................................................................................................................................................................51 

Fig.2.11: Mendor’s Discreet (left) & Roche’s Accu-Check Mobile with Attached Lancing Device (right) ....................................................................................................... 51 

Fig.2.12: BodyTel Europe’s GlucoTel BGM ...................................................................................................................................................................................................... 51 

Fig.2.13: Medisana’s GlucoDock Attached to an Apple iPhone ................................................................................................................................................................... 52 

Accuracy Standards ................................................................................................................................................................................53 

Market Forecast ...................................................................................................................................................................................... 54 

Summary: SMBG Growth Drivers, Restraints & Opportunities .................................................................................................................................................................... 55 

Fig.2.14: Global SMBG Market, 2011-2017E (US$ billion) ............................................................................................................................................................................. 55 

Fig.2.15: Global SMBG Market Growth Rates, 2012-2017E (%) .................................................................................................................................................................... 56 

2.2.2 Competitive Environment ..........................................................................................................................................56 

Public Companies’ BGM Sales, 2005-2011 (US$ million) ............................................................................................................................................................................. 57 

Fig.2.16: SMBG Market Share by Company, 2011 ......................................................................................................................................................................................... 57 

Fig.2.17: United States SMBG Market Share by Company, 2011 ................................................................................................................................................................... 58 

Fig.2.18: SMBG International Market Share by Company, 2011 ..................................................................................................................................................................58 

2.2.3 Market-Leading Self-Testing Blood Glucose Meters ...............................................................................................59 

1. Abbott’s Blood Glucose Monitors ....................................................................................................................................................59 

2. Arkray’s Glucocard Products ............................................................................................................................................................ 60 

3. Bayer’s Blood Glucose Monitoring Systems ...................................................................................................................................61 

4. Contour USB ........................................................................................................................................................................................ 62 

5. Contour, Contour TS, Contour Link and Breeze 2 ......................................................................................................................... 62 

6. DIDGET Meter ..................................................................................................................................................................................... 63 

7. Elite and Elite XL .................................................................................................................................................................................. 63 

LifeScan OneTouch Products ................................................................................................................................................................ 63 

May 2012


May 2012 



Nipro Diagnostics’ TRUE Products ...................................................................................................................................................... 66 

Roche Diabetes Care’s Products ...........................................................................................................................................................67 

2.2.4 Other Market Participants ..........................................................................................................................................68 

Competing Self-Testing Blood Glucose Monitoring Products .......................................................................................................................................................................68 

Product Highlights ..................................................................................................................................................................................71 

2.2.5 Products in Development ...........................................................................................................................................77 

Intuity Medical’s POGO Blood Glucose Monitoring System ........................................................................................................... 77 

Pepex Biomedical’s Trio Products ....................................................................................................................................................... 77 

2.3 CONTINUOUS GLUCOSE MONITORING .............................................................................................................................. 78 

Fig.2.19: Example of a CGM: Medtronic’s Guardian REAL-Time System ....................................................................................................................................................... 78 

2.3.1 The Benefits of CGM ....................................................................................................................................................78 

2.3.2 Barriers to Adoption ...................................................................................................................................................79 

The Cost of CGM ...................................................................................................................................................................................... 79 

2.3.3 Clinical Trial Results - Highlighting Benefits and Drawbacks .................................................................................79 

2.3.4 The TD1 Exchange: User Experiences of CGM ...........................................................................................................81 

2.3.5 CGM Market Trends and Opportunities ....................................................................................................................82 

Fig.2.20: Global CGM Market, 2006-2011 (US$ million) ..............................................................................................................................................................................82 

Fig.2.21: Percentage of CGM Sales Volumes by Hardware & Consumables, 2011 ........................................................................................................................................ 82 

Regional Adoption Rates, Regulatory and Reimbursement Environment ................................................................................. 83 

Fig.2.22: CGM Market by Region, 2011 ......................................................................................................................................................................................................... 83 

Future Prospects..................................................................................................................................................................................... 84 

Fig.2.23: Global CGM Market Forecast, 2011-2017E (US$ million)................................................................................................................................................................ 85 

Fig.2.24: Global CGM Market Forecast Growth Rates, 2011-2017E (%) .......................................................................................................................................................86 

Summary: CGM Benefits, Challenges & Opportunities ................................................................................................................................................................................86 

2.3.6 Competitive Environment ..........................................................................................................................................87 

Leading Companies’ Reported CGM Sales, 2006-2011 (US$ million) ........................................................................................................................................................... 87 

Fig.2.25: Global CGM Market Shares by Company, 2011 ..............................................................................................................................................................................88 

Fig.2.26: US CGM Market Shares by Company, 2011 ....................................................................................................................................................................................88 

Fig.2.27: International CGM Market Shares by Company, 2011 ...................................................................................................................................................................89 

2.3.7 Currently-Available Products .....................................................................................................................................89 

Medtronic’s Guardian REAL-Time CGM System ............................................................................................................................... 89 

DexCom’s CGMs ...................................................................................................................................................................................... 90 

Abbott’s FreeStyle Navigator ...............................................................................................................................................................91 

A Menarini Diagnostics’ GlucoDay S ....................................................................................................................................................92 

2.3.8 Products in Development ...........................................................................................................................................92 

Abbott’s Navigator II ...............................................................................................................................................................................92 

DexCom’s Research and Development ...............................................................................................................................................92 

New-Generation Implantable CGM Sensors ......................................................................................................................................93 

Minimally-Invasive CGM in Development ......................................................................................................................................... 95 

2.4 NON-INVASIVE GLUCOSE MONITORING ........................................................................................................................... 100 

2.4.1 Competitive Environment ....................................................................................................................................... 100 

2.4.2 AIMEDICS’ HypoMon ................................................................................................................................................101 

2.4.3 Biosign Technologies’ UFIT TEN-20 Non-Invasive Blood Pressure and Glucose Meter 101 

2.3.4 Biovotion’s Multisensor Glucose Monitoring System ............................................................................................102 

2.3.5 Integrity Applications’ GlucoTrack ..........................................................................................................................103 

Clinical Study Results ........................................................................................................................................................................... 103 

2.3.6 Optical Technologies.................................................................................................................................................105 

C8 MediSensors Optical Glucose Monitor ....................................................................................................................................... 105 

EyeSense’s Optical Sensor .................................................................................................................................................................. 105 

Freedom Meditech’s I-SugarX Glucose Monitoring System ......................................................................................................... 106 

Grove Instruments’ Grove Glucometer ............................................................................................................................................ 106 

Lein Applied Diagnostics .................................................................................................................................................................... 107 

LighTouch Medical’s Non-Invasive Glucose Monitor ..................................................................................................................... 107 

Massachusetts Institute of Technology’s Raman Spectroscopy System ................................................................................... 108 

Medtronic’s PreciSense Technology ................................................................................................................................................. 108 

v


vi 



OrSense’s NBM-200G Non-Invasive Blood Glucose Meter ........................................................................................................... 108 

St Louis Medical Devices Near-Infrared Light-Based System ....................................................................................................... 109 

Smart Tattoos ........................................................................................................................................................................................ 109 

2.3.7 Tear Fluid Glucose Sensors .......................................................................................................................................110 

Mayo Clinic, Arizona State University and BioAccel ........................................................................................................................110 

University of Washington and Microsoft Research ........................................................................................................................111 

The University of Western Ontario’s Glucose Monitoring Contact Lenses .................................................................................111 

2.3.8 Breath-Based Glucose Monitoring .........................................................................................................................112 

PositiveID’s EasyChek ...........................................................................................................................................................................112 

Xhale’s Breath-Based Glucose Monitor .............................................................................................................................................112 

Brown University and Saliva-Based Glucose Testing .....................................................................................................................112 

3.0 INSULIN DELIVERY PRODUCTS ...............................................................................................................114 

3.1 ADDRESSABLE PATIENT POPULATION ...............................................................................................................................116 

Fig.3.1: Percentage of US Diabetes Patients by Treatment Type, 2007-2009 ............................................................................................................................................. 116 

3.2 MARKET TRENDS ...................................................................................................................................................................117 

Insulin Delivery Market by Product Type 2005-2011 (US$ million) .............................................................................................................................................................117 

Fig.3.2: Global Insulin Delivery Market, 2005-2011 (US$ billion) ...............................................................................................................................................................117 

Fig.3.3: Global Insulin Delivery Market Growth Rates, 2006-2011 (%) ..................................................................................................................................................... 118 

Fig.3.4: Percentage of Insulin Delivery Market by Product Type, 2011 ....................................................................................................................................................... 118 

Fig.3.5: Insulin Delivery Market by Geographic Region, 2011 .................................................................................................................................................................... 119 

3.2.1 Competitive Environment ........................................................................................................................................120 

Key Companies’ Insulin Delivery Sales, 2006-2011 (US$ million) .............................................................................................................................................................. 120 

Fig.3.6: Insulin Delivery Market Share by Company, 2011 ......................................................................................................................................................................... 120 

3.3 FUTURE MARKET PROSPECTS ............................................................................................................................................ 121 

Summary: Insulin Delivery Market Growth Drivers, Restraints & Opportunities ...................................................................................................................................... 121 

Insulin Delivery Market Forecast by Product Type 2011-2017E (US$ million) ............................................................................................................................................. 122 

Fig.3.7: Global Insulin Delivery Market Forecast, 2011-2017 (US$ billion) ................................................................................................................................................. 122 

Fig.3.8: Global Insulin Delivery Market Estimated Growth Rates, 2012-2017 (%) .................................................................................................................................... 122 

Fig.3.9: Estimated Insulin Delivery Market by Product Type, 2017 ............................................................................................................................................................. 123 

3.4 MANUAL INSULIN INJECTION PRODUCTS ........................................................................................................................ 124 

Fig.3.10: Manual Insulin Delivery Method by Product Type, 2011 ............................................................................................................................................................. 124 

Fig.3.11: Percentage of Novo Nordisk Insulin Sold in Pens by Region, 2011 ............................................................................................................................................... 125 

Fig.3.12: Manual Insulin Delivery Market by Geographic Region, 2011 ..................................................................................................................................................... 125 

3.4.1 Insulin Pens ................................................................................................................................................................126 

Fig.3.13: Example Insulin Pen: Novo Nordisk’s NovoPen 4 ......................................................................................................................................................................... 126 

Fig.3.14: Global Insulin Pen Market: Disposable vs Reusable Pens, 2011 ................................................................................................................................................... 126 

Competitive Environment ..................................................................................................................................................................127 

Fig.3.15: Insulin Pen Use by Manufacturer, 2011 ........................................................................................................................................................................................ 127 

Currently-Available Products ............................................................................................................................................................. 128 

3.4.2 Needles and Syringes ................................................................................................................................................130 

Fig.3.16: Insulin Needles & Syringes Market by Manufacturer, 2011 ......................................................................................................................................................... 131 

Pen Needles ............................................................................................................................................................................................131 

3.5 INSULIN PUMPS .................................................................................................................................................................... 133 

Fig.3.17: Example Insulin Pump: Medtronic’s MiniMed Paradigm REAL-Time Revel ................................................................................................................................ 133 

Fig.3.18: Example Insulin Pump: Roche’s Accu-Check Spirit ...................................................................................................................................................................... 133 

Insulin Pump Market: Growth Drivers, Restraints & Opportunities ........................................................................................................................................................... 134 

3.5.1 The TD1 Exchange: User Experiences of CGM .........................................................................................................135 

3.5.2 Current Market Trends .............................................................................................................................................136 

Fig.3.19: Global Insulin Pump Market, 2005-2011 (US$ million) .............................................................................................................................................................. 136 

Fig.3.20: Global Insulin Pump Market Growth Rates, 2006-2011 (%) ...................................................................................................................................................... 136 

Fig.3.21: Insulin Pump Market by Product, 2011 ........................................................................................................................................................................................ 137 

Regional Perspective ............................................................................................................................................................................137 

Fig.3.22: Insulin Pump Market by Region, 2011 ......................................................................................................................................................................................... 137 

Fig.3.23: Insulin Pump Adoption Rates for Type 1 Diabetes Patients by Key Country, 2010 (%) ............................................................................................................... 138 

May 2012


May 2012 



Regulatory Environment - FDA Infusion Pump Improvement Initiative ................................................................................... 139 

Negative Publicity and the Potential for Cyber Attacks ................................................................................................................ 140 

Market Outlook ......................................................................................................................................................................................141 

Fig.3.24: Global Insulin Pump Market Forecast, 2011-2017 (US$ million) ................................................................................................................................................. 141 

Fig.3.25: Global Insulin Pump Market Estimated Growth Rates, 2012-2017 (%) ..................................................................................................................................... 141 

3.5.3 Competitive Environment ........................................................................................................................................142 

Key Companies’ Insulin Pump Sales, 2005-2011 (US$ million) .................................................................................................................................................................. 142 

Fig.3.26: Insulin Pump Market Shares, 2011 .............................................................................................................................................................................................. 143 

3.5.4 Currently-Available Insulin Pumps .........................................................................................................................143 

Animas Insulin Pumps ......................................................................................................................................................................... 143 

Asante Solutions’ Pearl Insulin Pump ............................................................................................................................................... 144 

D Medical Industries’ Spring Pumps and Infusion Sets ................................................................................................................. 144 

Medtronic’s MiniMed Paradigm Revel Insulin Pump and Infusion Sets .................................................................................... 145 

Sooil Development’s Diabecare Insulin Pumps .............................................................................................................................. 146 

Roche Insulin Pumps ........................................................................................................................................................................... 146 

Tandem Diabetes Care’s t:slim Insulin Delivery System .................................................................................................................147 

Insulin Delivery Patch Pumps .............................................................................................................................................................147 

3.5.5 Products in Development .........................................................................................................................................150 

Becton Dickinson-JDRF Micro-Needle Technology ...................................................................................................................... 150 

CeQur’s Insulin Patch Infuser ............................................................................................................................................................. 150 

D Medical Industries’ Spring Hybrid Patch Pump .......................................................................................................................... 150 

Debiotech’s JewelPUMP .......................................................................................................................................................................151 

Insulet’s Second-Generation OmniPod ............................................................................................................................................151 

Insuline Medical’s InsuPatch and InsuPad ........................................................................................................................................151 

Roche’s SOLO Micropump .................................................................................................................................................................. 152 

3.6 ALTERNATIVE INSULIN DELIVERY DEVICES....................................................................................................................... 153 

3.6.1 Generex Biotechnology’s Oral-lyn ...........................................................................................................................153 

3.6.2 Insulin Inhalers ..........................................................................................................................................................154 

Development Considerations ............................................................................................................................................................ 154 

Fig.3.27: MannKind’s Dreamboat (Gen2) Insulin Inhaler .......................................................................................................................................................................... 155 

4.0 COMBINED CGM-INSULIN PUMP SYSTEMS ...........................................................................................157 

4.1 CURRENTLY-AVAILABLE PRODUCTS ................................................................................................................................. 158 

4.1.1 Medtronic’s Paradigm Integrated Diabetes Management Products ....................................................................158 

Paradigm REAL-Time Revel ................................................................................................................................................................ 158 

Fig.4.1: MiniMed Paradigm REAL-Time System .......................................................................................................................................................................................... 158 

Enlite CGM Sensor ................................................................................................................................................................................ 159 

Clinical Trials .......................................................................................................................................................................................... 159 

ONSET Study ......................................................................................................................................................................................... 160 

REAL Trend Study ................................................................................................................................................................................. 160 

4.1.2 Animas Vibe ...............................................................................................................................................................161 

4.2 PRODUCTS IN DEVELOPMENT ............................................................................................................................................ 162 

4.2.1 D Medical Industries’ Combined CGM-Pump System ............................................................................................162 

5.0 ARTIFICIAL PANCREAS TECHNOLOGY .................................................................................................. 163 

5.1 SEMI-CLOSED LOOP SYSTEMS ............................................................................................................................................ 165 

5.1.2 Medtronic’s Paradigm Veo System with Low Glucose Suspend ............................................................................165 

Fig.5.1: Medtronic’s Paradigm Veo System with Low Glucose Suspend ..................................................................................................................................................... 165 

ASPIRE Study ........................................................................................................................................................................................ 166 

5.2 RESEARCH & DEVELOPEMNT ............................................................................................................................................. 167 

5.2.1 FDA Artificial Pancreas Development Guidelines ..................................................................................................167 

5.2.2 Key Closed-Loop Development Projects .................................................................................................................168 

The Juvenile Diabetes Research Foundation’s Artificial Pancreas Project ............................................................................... 168 

Mayo Clinic ............................................................................................................................................................................................ 172 

UC Santa Barbara, Sansum Diabetes Research Institute, Mayo Clinic, Universities of Virginia & Padova 172 

AP@home Project ................................................................................................................................................................................. 172 

vii


viii 



MD-Logic Artificial Pancreas System ................................................................................................................................................ 173 

Medtronic’s Closed-Loop System .......................................................................................................................................................174 

Rensselaer Polytechnic Institute .......................................................................................................................................................175 

6.0 POC MANUFACTURERS ...........................................................................................................................176 

6.1 POC COMPANY DIRECTORY................................................................................................................................................. 176 

6.2 LEADING COMPANY PROFILES ........................................................................................................................................... 184 

6.2.1 Abbott Laboratories .................................................................................................................................................184 

Recent Key Events .......................................................................................................................................................................................................................................184 

Blood Glucose Monitors ..................................................................................................................................................................... 185 

In Development - Navigator II CGM System .................................................................................................................................... 186 

Alliance with Insulet............................................................................................................................................................................. 187 

Litigation ............................................................................................................................................................................................... 187 

Financial Performance ........................................................................................................................................................................ 188 

Abbott Diabetes Care Sales by Region, 2006-2011 (US$ million) ..............................................................................................................................................................188 

Fig.6.1: Percentage of Abbott Diabetes Care Revenue by Region, 2011 .....................................................................................................................................................188 

6.2.2 Arkray .........................................................................................................................................................................189 

Recent Key Events ....................................................................................................................................................................................................................................... 189 

Blood Glucose Self-Testing ................................................................................................................................................................. 189 

Current Alliances and Contracts .........................................................................................................................................................191 

6.2.3 Bayer ...........................................................................................................................................................................192 


Blood Glucose Monitoring Systems .................................................................................................................................................. 192 

Current Alliances .................................................................................................................................................................................. 194 

Litigation ................................................................................................................................................................................................ 195 


Bayer Diabetes Care Revenue, 2005-2011 (EUR million) ............................................................................................................................................................................ 195 

6.2.4 Becton, Dickinson and Company .............................................................................................................................196 


BD Diabetes Care Products ................................................................................................................................................................. 196 

Collaboration with the JDRF .............................................................................................................................................................. 197 

Litigation with Insulet ......................................................................................................................................................................... 197 


BD Diabetes Care Sales by Region, 2006-2011 (US$ million) ..................................................................................................................................................................... 198 

Fig.6.2: Percentage of BD Diabetes Care’s Revenue by Region, 2011 ......................................................................................................................................................... 198 

6.2.5 DexCom ......................................................................................................................................................................199 


SEVEN PLUS CGM System .................................................................................................................................................................... 200 

GlucoClear ............................................................................................................................................................................................. 201 

Research and Development ............................................................................................................................................................... 201 

SweetSpot Diabetes Care Acquisition ............................................................................................................................................. 201 


Litigation with Abbott ........................................................................................................................................................................ 203 


DexCom - Operating Results, 2007-2011 (US$ thousands) ........................................................................................................................................................................205 

6.2.6 Insulet ........................................................................................................................................................................ 206 


OmniPod Insulin Management System ........................................................................................................................................... 207 


Acquisition of Neighborhood Diabetes ........................................................................................................................................... 209 

Litigation with Becton, Dickinson and Company .......................................................................................................................... 209 


Insulet - Operating Results, 2007-2011 (US$ thousands) ........................................................................................................................................................................... 210 

6.2.7 Johnson & Johnson ...................................................................................................................................................211 


May 2012


May 2012 



Animas Operations ...............................................................................................................................................................................212 

LifeScan Operations ..............................................................................................................................................................................214 

Financial Performance .........................................................................................................................................................................217 

J&J Diabetes Care Revenue, 2006-2011 (US$ million) ............................................................................................................................................................................... 218 

Fig.6.3: J&J Diabetes Care Sales by Region, 2011 ....................................................................................................................................................................................... 218 

Fig.6.4: J&J Diabetes Care Sales, 2004-2011 (US$ million) ........................................................................................................................................................................ 218 

6.2.8 Medtronic...................................................................................................................................................................219 


Integrated Diabetes Management Products .................................................................................................................................. 220 

Guardian REAL-Time CGM System .................................................................................................................................................... 221 

iPro Professional Use CGM Products ................................................................................................................................................. 222 

Enlite CGM Sensor ................................................................................................................................................................................ 222 

MiniMed Paradigm Revel Insulin Pump and Infusion Sets .......................................................................................................... 222 

CareLink Software ................................................................................................................................................................................ 223 

Blood Glucose Meters ......................................................................................................................................................................... 223 

Clinical Trials .......................................................................................................................................................................................... 224 

Research and Development ............................................................................................................................................................... 225 

Alliance with Bayer .............................................................................................................................................................................. 225 


Fig.6.5: Medtronic Diabetes Revenue, 2005-2011 (US$ million) ................................................................................................................................................................226 

Medtronic - Diabetes Sales by Region, 2008-2011 (US$ million) ............................................................................................................................................................... 227 

Fig.6.6: Medtronic Diabetes Revenue by Region, 2011 .............................................................................................................................................................................. 227 

Fig.6.7: Medtronic Diabetes Revenue by Product Type, 2010* ................................................................................................................................................................... 227 

6.2.9 Nipro Diagnostics .................................................................................................................................................... 229 


Blood Glucose Monitoring Products ................................................................................................................................................ 230 

Blood Glucose Monitors ...................................................................................................................................................................... 230 

6.2.10 Roche Diabetes Care ...............................................................................................................................................232 


Diabetes Care Products ....................................................................................................................................................................... 233 

Accu-Chek Combo BGM and Pump System .................................................................................................................................... 234 

Insulin Pumps ........................................................................................................................................................................................ 234 

Data Management Tools ..................................................................................................................................................................... 235 

In Development - SOLO Micropump ................................................................................................................................................. 235 

Current Alliances and Contracts ........................................................................................................................................................ 236 

Litigation ................................................................................................................................................................................................ 236 


Roche Diabetes Care Sales by Product, 2010-2011 (SFr million) ................................................................................................................................................................ 237 

Roche Diabetes Care Sales by Region, 2006-2011 (SFr million) ................................................................................................................................................................. 237 

Fig.6.8: Roche Diabetes Care - Revenue by Product Line, 2011 ..................................................................................................................................................................238 

Fig.6.9: Roche Diabetes Care - Revenue by Region, 2011 ...........................................................................................................................................................................238 

6.2.11 Ypsomed .................................................................................................................................................................. 239 


mylife Diabetes Care Products .......................................................................................................................................................... 240 

Ypsomed Delivery Systems ................................................................................................................................................................ 240 

Acquisition of ICU Medical’s Orbit Infusion Set Business .............................................................................................................. 241 



Ypsomed - Operating Results, Y/E 31st March 2007-2011 (SFr millions) .................................................................................................................................................... 243 

Ypsomed - Results by Business Segment, Y/E 31st March 2009-2011 (SFr millions) .................................................................................................................................. 243 

Ypsomed - Revenue by Geographic Region, Y/E 31st March 2009-2011 (SFr millions) ..............................................................................................................................244 

Fig.6.10: Ypsomed - Revenue by Business Segment, Fiscal 2010 ...............................................................................................................................................................244 

Fig.6.11: Ypsomed - Revenue by Geographic Location, Fiscal 2010 ........................................................................................................................................................... 245 

7.0 APPENDICES ............................................................................................................................................. 246 

ix


x 



7.1 LIST OF ABBREVIATIONS ......................................................................................................................................................246 

7.2 - REPORT METHODOLOGY .................................................................................................................................................. 247 

Sources ................................................................................................................................................................................247 

Market forecasts ................................................................................................................................................................ 248 

VOLUME II - DIABETES TECHNOLOGY AND INTELLECTUAL PROPERTY ANALYSIS 

1.0 SUMMARY ............................................................................................................................................... 251 

Figure 1.1 – Diabetes Landscape by Technology........................................................................................................................................................................................ 252 

Figure 1.2 – High Level Overview of Diabetes Patent Activity ...................................................................................................................................................................254 

Figure 1.3 – Bar Chart of Totals for each Technology Group ...................................................................................................................................................................... 255 

Figure 1.4 – Top 20 Assignees Patents from this Study .............................................................................................................................................................................. 256 

Figure 1.5 - Blood Extraction by Priority Date by Assignee ........................................................................................................................................................................ 257 

Figure 1.6 – Number of Patents versus Revenue for Highlighted Companies ...........................................................................................................................................258 

Figure 1.7 – Litigation Analysis .................................................................................................................................................................................................................. 259 

Table 1.1 – Table of Highlighted Companies and Technologies .................................................................................................................................................................260 

2.0 INTRODUCTION ...................................................................................................................................... 262 

3.0 TECHNOLOGY ......................................................................................................................................... 264 

Figure 3.1 – Diabetes Landscape by Technology ....................................................................................................................................................................................... 265 

Figure 3.2 – Self Monitoring of Blood Glucose ...........................................................................................................................................................................................266 

Figure 3.3 – Blood Glucose Test Strip Operation ........................................................................................................................................................................................ 267 

Figure 3.4 – Continuous Glucose Monitoring (CGM) .................................................................................................................................................................................. 267 

Figure 3.5 – Artificial Pancreas Representative Diagram .......................................................................................................................................................................... 269 

4.0 OVERVIEW OF PATENT ACTIVITIES ....................................................................................................... 270 

Figure 4.1 – High Level Overview of Diabetes Patent Activity ................................................................................................................................................................... 271 

4.1 Analysis of Patents Sorted by this Study .......................................................................................................................... 273 

Figure 4.2 – Bar Chart of Totals for each Technology Group...................................................................................................................................................................... 273 

Figure 4.3 – Top 20 Assignees Patents from This Study ............................................................................................................................................................................. 274 

Figure 4.4 – Patents by Priority Date ......................................................................................................................................................................................................... 275 

Figure 4.5 – Priority Date by Top 5 Companies .......................................................................................................................................................................................... 276 

Figure 4.6 – Patents by Published Date .....................................................................................................................................................................................................277 

Figure 4.7 – Patents by Source Jurisdiction ............................................................................................................................................................................................... 278 

Figure 4.8 – Top 10 IPC Codes from the Patents Analyzed ......................................................................................................................................................................... 279 

Figure 4.9 – Total U.S. Patents by Assignee ...............................................................................................................................................................................................280 

Figure 4.10 – USP Classification Analysis within the U.S. Dataset ............................................................................................................................................................. 281 

5.0 PATENT ANALYSIS BY TECHNOLOGY SUBCATEGORY ......................................................................... 282 

5.1 Detection and Monitoring – Periodic – Invasive – Blood Extraction ..........................................................................283 

Figure 5.1 – Blood Extraction – Top Assignees ..........................................................................................................................................................................................283 

Priority Date by Year and Source: ...................................................................................................................................................... 284 

Figure 5.2 - Blood Extraction by Priority Date ............................................................................................................................................................................................284 

Priority Date by Year by Top 5 Assignees within the Subcategory: ............................................................................................ 285 

Figure 5.3 - Blood Extraction by Priority Date by Assignee ........................................................................................................................................................................ 285 

Published Date by Year and Source: ................................................................................................................................................. 286 

Figure 5.4 - Blood Extraction by Published Date ........................................................................................................................................................................................286 

IPC Analysis – Top 10 Codes: ............................................................................................................................................................... 287 

Figure 5.5 - Blood Extraction by IPC Code .................................................................................................................................................................................................. 287 

USPC Analysis – Top 10 Codes: ........................................................................................................................................................... 288 

Figure 5.6 - Blood Extraction by USPC Code ...............................................................................................................................................................................................288 

Figure 5.7 – Blood Extraction - Text Clustering Analysis ...........................................................................................................................................................................289 

Source Jurisdiction: .............................................................................................................................................................................. 290 

Figure 5.8 - Blood Extraction by Source Jurisdiction ..................................................................................................................................................................................290 

Top Patents ............................................................................................................................................................................................ 291 

Table 5.1 - Top Patents Identified in the Blood Extraction Group ............................................................................................................................................................... 291 

May 2012


May 2012 



US6461496B1: Abbott Laboratories ................................................................................................................................292 

Figure 5.9 – Representative Image in US6461496 ..................................................................................................................................................................................... 292 

Figure 5.10 – Top 20 Companies Citing US6461496 .................................................................................................................................................................................. 293 

US5916230A: Bayer AG .................................................................................................................................................... 294 

Figure 5.11 – Representative Images of US5916230 ..................................................................................................................................................................................294 

Figure 5.12 – Top 20 Companies Citing US5916230 ................................................................................................................................................................................... 295 

5.2 Detection and Monitoring – Periodic – Invasive – Test Strips ......................................................................................296 

Figure 5.13 – Test Strips – Top Assignees ...................................................................................................................................................................................................296 

Priority Date by Year and Source: ...................................................................................................................................................... 297 

Figure 5.14 - Test Strips by Priority Date ..................................................................................................................................................................................................... 297 

Priority Date by Year by Assignee: .................................................................................................................................................... 297 

Figure 5.15 - Test Strips by Priority Date by Assignee ................................................................................................................................................................................. 297 

Published Date by Year: ...................................................................................................................................................................... 298 

Figure 5.16 - Test Strips by Published Date .................................................................................................................................................................................................298 


Figure 5.17 - Test Strips by IPC Code ............................................................................................................................................................................................................299 


Figure 5.18 - Test Strips by USPC Code ........................................................................................................................................................................................................300 

Text Clustering Analysis: ..................................................................................................................................................................... 301 

Figure 5.19 – Test Strips - Text Clustering Analysis ..................................................................................................................................................................................... 301 


Figure 5.20 - Test Strips by Source Jurisdiction ...........................................................................................................................................................................................302 

Top Patents ............................................................................................................................................................................................ 303 

Table 5.2 - Top Patents Identified in the Test Strips Group .........................................................................................................................................................................303 

US5496453A: Arkray, Inc. ................................................................................................................................................ 304 

Figure 5.21 – Representative Image in US5496453 ...................................................................................................................................................................................304 

Figure 5.22 – Top 20 Companies Citing US5496453 ..................................................................................................................................................................................305 

US5563042: Johnson & Johnson ...................................................................................................................................... 306 



5.3 Detection and Monitoring – Periodic – Invasive – Devices ..........................................................................................308 

Figure 5.25 – Devices – Top Assignees ......................................................................................................................................................................................................308 

Priority Date by Year: ........................................................................................................................................................................... 309 

Figure 5.26 - Devices by Priority Date .........................................................................................................................................................................................................309 


Figure 5.27 - Devices by Priority Date by Assignee .....................................................................................................................................................................................309 

Published Date by Year and Source: ..................................................................................................................................................310 

Figure 5.28 - Devices by Published Date ..................................................................................................................................................................................................... 310 

IPC Analysis – Top 10 Codes: ................................................................................................................................................................311 

Figure 5.29 - Devices by IPC Code ................................................................................................................................................................................................................311 

USPC Analysis – Top 10 Codes: ............................................................................................................................................................312 

Figure 5.30 - Devices by USPC Code ............................................................................................................................................................................................................ 312 

Text Clustering Analysis: ......................................................................................................................................................................313 

Figure 5.31 – Devices - Text Clustering Analysis ......................................................................................................................................................................................... 313 

Source Jurisdiction: ...............................................................................................................................................................................314 

Figure 5.32 - Devices by Source Jurisdiction ............................................................................................................................................................................................... 314 

Top Patents .............................................................................................................................................................................................315 

Table 5.3 - Top Patents Identified in the Devices Group ............................................................................................................................................................................. 315 

US6233471: Johnson & Johnson ......................................................................................................................................316 

Figure 5.33 – Representative Image in US6233471 ................................................................................................................................................................................... 316 


5.4 Detection and Monitoring – Periodic – Minimally Invasive – Interstitial Fluid ......................................................... 318 

Figure 5.35 – Interstitial Fluid – Top Assignees ......................................................................................................................................................................................... 318 

Priority Date by Year: ............................................................................................................................................................................319 

Figure 5.36 - Interstitial Fluid by Priority Date ........................................................................................................................................................................................... 319 

xi


xii 


Priority Date by Year by Assignee: .....................................................................................................................................................319 

Figure 5.37 - Interstitial Fluid by Priority Date ........................................................................................................................................................................................... 319 


Figure 5.38 - Interstitial Fluid by Published Date ....................................................................................................................................................................................... 320 

IPC Analysis - Top 10 Codes: ...............................................................................................................................................321 

Figure 5.39 - Interstitial Fluid by IPC Code .................................................................................................................................................................................................. 321 


Figure 5.40 - Interstitial Fluid by USPC Code ............................................................................................................................................................................................... 322 


Figure 5.41 – Interstitial Fluid - Text Clustering Analysis ........................................................................................................................................................................... 323 


Figure 5.42 - Interstitial Fluid by Source Jurisdiction .................................................................................................................................................................................. 324 

Top Patents ............................................................................................................................................................................................ 325 

Table 5.4 - Top Patents Identified in the Interstitial Fluid Group ................................................................................................................................................................ 325 

US5582184: Alere Incorporated ......................................................................................................................................326 



5.5 Detection and Monitoring – Periodic – Minimally Invasive – Skin Diffusion ............................................................ 328 

Figure 5.45 – Skin Diffusion – Top Assignees ............................................................................................................................................................................................ 328 


Figure 5.46 - Skin Diffusion by Priority Date .............................................................................................................................................................................................. 329 


Figure 5.47 - Skin Diffusion by Priority Date by Assignee ........................................................................................................................................................................... 329 


Figure 5.48 - Skin Diffusion by Published Date .......................................................................................................................................................................................... 330 


Figure 5.49 - Skin Diffusion by IPC Code ..................................................................................................................................................................................................... 331 


Figure 5.50 - Skin Diffusion by USPC Code .................................................................................................................................................................................................. 332 


Figure 5.51 – Skin Diffusion - Text Clustering Analysis .............................................................................................................................................................................. 333 


Figure 5.52 - Skin Diffusion by Source Jurisdiction ..................................................................................................................................................................................... 334 

Top Patents ............................................................................................................................................................................................ 334 

Table 5.5 - Top Patents Identified in the Skin Diffusion Group ................................................................................................................................................................... 334 

US6454710: Johnson & Johnson ......................................................................................................................................335 



5.6 Detection and Monitoring – Periodic – Non Invasive – Optical................................................................................... 337 

Figure 5.55 – Non Invasive - Optical – Top Assignees ............................................................................................................................................................................... 337 


Figure 5.56 - Non Invasive - Optical by Priority Date .................................................................................................................................................................................. 338 


Figure 5.57 - Non Invasive - Optical by Priority Date .................................................................................................................................................................................. 338 


Figure 5.58 - Non Invasive - Optical by Published Date .............................................................................................................................................................................. 339 


Figure 5.59 - Non Invasive - Optical by IPC Code ........................................................................................................................................................................................340 


Figure 5.60 - Non Invasive - Optical by USP Class Code .............................................................................................................................................................................. 341 


Figure 5.61 – Non Invasive - Optical - Text Clustering Analysis ................................................................................................................................................................. 342 


Figure 5.62 - Non Invasive - Optical by Source Jurisdiction ........................................................................................................................................................................ 343 

Top Patents ............................................................................................................................................................................................344 


May 2012


May 2012 



Table 5.6- Top Patents Identified in the Non Invasive Optical Group .........................................................................................................................................................344 

US5743262: Masimo Corporation ................................................................................................................................... 345 


Figure 5.64 – Top 20 Companies Citing US5743263 ...................................................................................................................................................................................346 

US6040578: Sensys Medical Inc ........................................................................................................................................347 

Figure 5.65 – Patent Diagram of US6040578 ............................................................................................................................................................................................ 347 


5.7 Detection and Monitoring – Periodic – Non Invasive – Other .....................................................................................349 

Figure 5.67 – Non-Invasive Other – Top Assignees ...................................................................................................................................................................................349 


Figure 5.68 – Non-Invasive Other by Priority Date .................................................................................................................................................................................... 350 


Figure 5.69 - Non-Invasive Other by Priority Date by Assignee.................................................................................................................................................................. 350 


Figure 5.70 - Non-Invasive Other by Published Date ................................................................................................................................................................................. 351 


Figure 5.71 - Non Invasive Other by IPC Code ............................................................................................................................................................................................. 352 


Figure 5.72 - Non Invasive Other by USPC Code.......................................................................................................................................................................................... 353 


Figure 5.73 – Non Invasive Other - Text Clustering Analysis ...................................................................................................................................................................... 354 


Figure 5.74 – Non-Invasive - Other by Source Jurisdiction ........................................................................................................................................................................ 355 

Top Patents ............................................................................................................................................................................................ 355 

Table 5.7 - Top Patents Identified in the Non Invasive – Other Group ....................................................................................................................................................... 355 

US6572542: Medtronic Inc ................................................................................................................................................356 



5.8 Detection and Monitoring – Continuous – Non-Implanted ........................................................................................ 358 

Figure 5.77 – Continuous Non-Implanted – Top Assignees ...................................................................................................................................................................... 358 


Figure 5.78 - Continuous Non-Implanted by Priority Date ........................................................................................................................................................................ 359 


Figure 5.79 - Continuous Non-Implanted by Priority Date by Assignee .................................................................................................................................................... 359 


Figure 5.80 - Continuous Non-Implanted by Published Date ....................................................................................................................................................................360 


Figure 5.81 - Continuous Non-Implanted by IPC Code ............................................................................................................................................................................... 361 


Figure 5.82 - Continuous Non-Implanted by USPC Code ...........................................................................................................................................................................362 

Figure 5.83 – Continuous Non-Implanted -Text Clustering Analysis ......................................................................................................................................................... 363 


Figure 5.84 - Continuous Non-Implanted by Source Jurisdiction ..............................................................................................................................................................364 

Top Patents ............................................................................................................................................................................................ 365 

Table 5.8 - Top Patents Identified in the Continuous Non-Implanted Group ............................................................................................................................................. 365 

US6931327: Dexcom, Inc. ................................................................................................................................................. 366 


Figure 5.86 – Top 20 Companies Citing US6931327 ................................................................................................................................................................................... 367 

5.9 Detection and Monitoring – Continuous – Implanted ..................................................................................................368 

Figure 5.87 – Continuous Implanted – Top Assignees ..............................................................................................................................................................................368 


Figure 5.88 - Continuous Implanted by Priority Date ................................................................................................................................................................................ 369 


Figure 5.89 - Continuous Implanted by Priority Date by Assignee ............................................................................................................................................................. 369 


xiii


xiv 



Figure 5.90 - Continuous Implanted by Published Date............................................................................................................................................................................. 370 


Figure 5.91 - Continuous Implanted by IPC Code ....................................................................................................................................................................................... 371 


Figure 5.92 - Continuous Implanted by USPC Code .................................................................................................................................................................................... 372 


Figure 5.93 – Continuous Implanted - Text Clustering Analysis ................................................................................................................................................................ 373 


Figure 5.94 - Continuous Implanted by Source Jurisdiction ....................................................................................................................................................................... 374 

Top Patents ............................................................................................................................................................................................ 375 

Table 5.9 - Top Patents Identified in the Continuous Implanted Group ..................................................................................................................................................... 375 



5.10 Treatment – Manual – Syringe ........................................................................................................................................ 378 

Figure 5.97 – Syringe – Top Assignees....................................................................................................................................................................................................... 378 


Figure 5.98 - Syringe by Priority Date ......................................................................................................................................................................................................... 379 


Figure 5.99 - Syringe by Priority Date by Assignee ..................................................................................................................................................................................... 379 


Figure 5.100 - Syringe by Published Date ...................................................................................................................................................................................................380 


Figure 5.101 - Syringe by IPC Code .............................................................................................................................................................................................................. 381 


Figure 5.102 - Syringe by USPC Code ..........................................................................................................................................................................................................382 


Figure 5.103 – Syringe - Text Clustering Analysis .......................................................................................................................................................................................383 


Figure 5.104 - Syringe by Source Jurisdiction .............................................................................................................................................................................................384 

Top Patents ............................................................................................................................................................................................ 384 

Table 5.10 - Top Patents Identified in the Syringe Group ............................................................................................................................................................................384 

US6254586: Medtronic, Inc. ............................................................................................................................................ 385 

Figure 5.105 – Representative Image in US6254586 .................................................................................................................................................................................385 

Figure 5.106 – Top 20 Companies Citing US6254586 ................................................................................................................................................................................386 

5.11 Treatment – Manual – Pen................................................................................................................................................387 

Figure 5.107 – Pen – Top Assignees ........................................................................................................................................................................................................... 387 


Figure 5.108 - Pen by Priority Date .............................................................................................................................................................................................................388 


Figure 5.109 - Pen by Priority Date by Assignee .........................................................................................................................................................................................388 


Figure 5.110 - Pen by Published Date .........................................................................................................................................................................................................389 


Figure 5.111 - Pen by IPC Code ....................................................................................................................................................................................................................390 


Figure 5.112 - Pen by USPC Code ................................................................................................................................................................................................................. 391 


Figure 5.113 – Pen - Text Clustering Analysis ............................................................................................................................................................................................. 392 


Figure 5.114 - Pen by Source Jurisdiction .................................................................................................................................................................................................... 393 

Top Patents ............................................................................................................................................................................................ 394 

Table 5.11 - Top Patents Identified in the Pen Group ..................................................................................................................................................................................394 

US6192891: Becton, Dickinson and Company ................................................................................................................395 

Figure 5.115 – Representative Image in US6192891 .................................................................................................................................................................................. 395 

Figure 5.116 – Top 20 Companies Citing US6192891 .................................................................................................................................................................................396 

May 2012


May 2012 



US5514097: Roche Holding Ltd. .......................................................................................................................................397 

Figure 5.117 – Representative Image in US5514097 .................................................................................................................................................................................. 397 


5.12 Treatment – Manual - Patch .............................................................................................................................................399 

Figure 5.119 – Patch – Top Assignees ........................................................................................................................................................................................................399 

Priority Date by Year: ...........................................................................................................................................................................400 

Figure 5.120 - Patch by Priority Date ..........................................................................................................................................................................................................400 

Priority Date by Year by Assignee: ....................................................................................................................................................400 

Figure 5.121 - Patch by Priority Date by Assignee ......................................................................................................................................................................................400 


Figure 5.122 - Patch by Published Date ......................................................................................................................................................................................................401 

IPC Analysis– Top 10 Codes: .............................................................................................................................................. 402 

Figure 5.123 - Patch by IPC Code .................................................................................................................................................................................................................402 


Figure 5.124 - Patch by USPC Code ..............................................................................................................................................................................................................403 

Text Clustering Analysis: .....................................................................................................................................................................404 

Figure 5.125 – Patch - Text Clustering Analysis ..........................................................................................................................................................................................404 


Figure 5.126 - Patch by Source Jurisdiction ................................................................................................................................................................................................405 

Top Patents ............................................................................................................................................................................................ 405 

Table 5.12 - Top Patents Identified in the Patch Group ...............................................................................................................................................................................405 

US6682757: Purdue Pharma LP ....................................................................................................................................... 406 



5.13 Treatment – Manual – Other ...........................................................................................................................................408 

Figure 5.129 – Treatment - Other – Top Assignees ....................................................................................................................................................................................408 


Figure 5.130 – Treatment – Other by Priority Date ...................................................................................................................................................................................409 

Priority Date by Year by Assignee: ....................................................................................................................................................409 

Figure 5.131 – Treatment – Other by Priority Date by Assignee ................................................................................................................................................................409 

Published Date by Year: .......................................................................................................................................................................410 

Figure 5.132 - Treatment – Other by Published Date ................................................................................................................................................................................. 410 


Figure 5.133 – Treatment – Other by IPC Code .......................................................................................................................................................................................... 411 


Figure 5.134 – Treatment - Other by USPC Code ........................................................................................................................................................................................ 412 

Text Clustering Analysis: ......................................................................................................................................................................413 

Figure 5.135 – Treatment – Other - Text Clustering Analysis..................................................................................................................................................................... 413 


Figure 5.136 – Treatment - Other by Source Jurisdiction ........................................................................................................................................................................... 414 

Top Patents .............................................................................................................................................................................................414 

Table 5.13 - Top Patents Identified in the Treatment – Other Group ......................................................................................................................................................... 414 

US6313093: Novartis AG ...................................................................................................................................................415 

Figure 5.137 – Top 20 Companies Citing US6313093 ................................................................................................................................................................................. 415 

5.14 Treatment – Automatic – External Pump ...................................................................................................................... 416 

Figure 5.138 – External Pump – Top Assignees ......................................................................................................................................................................................... 416 


Figure 5.139 - External Pump by Priority Date ........................................................................................................................................................................................... 417 

Priority Date by Year by Assignee: .....................................................................................................................................................417 

Figure 5.140 - External Pump by Priority Date by Assignee ....................................................................................................................................................................... 417 


Figure 5.141 - External Pump by Published Date ....................................................................................................................................................................................... 418 


Figure 5.142 - External Pump by IPC Code .................................................................................................................................................................................................. 419 


xv


xvi 


Figure 5.143 - External Pump by USPC Code............................................................................................................................................................................................... 420 


Figure 5.144 – External Pump - Text Clustering Analysis........................................................................................................................................................................... 421 


Figure 5.145 - External Pump by Source Jurisdiction ................................................................................................................................................................................. 422 

Top Patents ............................................................................................................................................................................................ 422 

Table 5.14 - Top Patents Identified in the External Pump Group ................................................................................................................................................................ 422 

US6740059: Insulet Corporation Devices ....................................................................................................................... 423 

Figure 5.146 – Representative Image in US6740059 ................................................................................................................................................................................. 423 


5.15 Treatment – Automatic – Implanted Pump .................................................................................................................. 425 

Figure 5.148 – Implanted Pump – Top Assignees ..................................................................................................................................................................................... 425 


Figure 5.149 - Implanted Pump by Priority Date ........................................................................................................................................................................................ 426 


Figure 5.150 - Implanted Pump by Priority Date by Assignee .................................................................................................................................................................... 426 


Figure 5.151 - Implanted Pump by Published Date .................................................................................................................................................................................... 427 


Figure 5.152 - Implanted Pump by IPC Code .............................................................................................................................................................................................. 428 

USPC Analysis– Top 10 Codes: .......................................................................................................................................... 429 

Figure 5.153 - Implanted Pump by USPC Code ........................................................................................................................................................................................... 429 


Figure 5.154 – Implanted Pump - Text Clustering Analysis ....................................................................................................................................................................... 430 


Figure 5.155 - Implanted Pump by Source Jurisdiction .............................................................................................................................................................................. 431 

Top Patents ............................................................................................................................................................................................ 431 

Table 5.15 - Top Patents Identified in the Implanted Pump Group ............................................................................................................................................................ 431 

US5569186: Medtronic, Inc. ............................................................................................................................................. 432 

Figure 5.156 – Representative Image in US5569186.................................................................................................................................................................................. 432 


5.16 Treatment – Automatic – SW and Algorithms ..............................................................................................................434 

Figure 5.158 – SW/Algorithm – Top Assignees .......................................................................................................................................................................................... 434 


Figure 5.159 - SW/Algorithm by Priority Date ............................................................................................................................................................................................ 435 


Figure 5.160 - SW/Algorithm by Priority Date by Assignee ........................................................................................................................................................................ 435 


Figure 5.161 - SW/Algorithm by Published Date ........................................................................................................................................................................................ 436 


Figure 5.162 - SW/Algorithm by IPC Code ................................................................................................................................................................................................... 437 


Figure 5.163 - SW/Algorithm by USPC Code ............................................................................................................................................................................................... 438 


Figure 5.164 – SW/Algorithm - Text Clustering Analysis ........................................................................................................................................................................... 439 

Source Jurisdiction: ..............................................................................................................................................................................440 

Figure 5.165 - SW/Algorithm by Source Jurisdiction ..................................................................................................................................................................................440 

Top Patents ............................................................................................................................................................................................ 441 

Table 5.16 - Top Patents Identified in the SW/Algorithms Group ...............................................................................................................................................................441 

US6168563: Robert Bosch GmbH ..................................................................................................................................... 442 

Figure 5.166 – Front Page Diagram of US6168573 ....................................................................................................................................................................................442 


US6809653: Medtronic, Inc. .............................................................................................................................................. 444 


Figure 5.169 – Top 20 Companies Citing US6809653 ................................................................................................................................................................................445 


May 2012

Diabetes Landscape: Table of Contents 

5.17 Artificial Pancreas ..............................................................................................................................................................446 

Figure 5.170 – Artificial Pancreas – Top Assignees ....................................................................................................................................................................................446 


Figure 5.171 - Artificial Pancreas by Priority Date ......................................................................................................................................................................................447 


Figure 5.172 - Artificial Pancreas by Priority Date by Assignee ..................................................................................................................................................................447 

Published Date by Year: ......................................................................................................................................................................448 

Figure 5.173 - Artificial Pancreas by Published Date ..................................................................................................................................................................................448 


Figure 5.174 - Artificial Pancreas by IPC Code .............................................................................................................................................................................................449 

USPC Analysis– Top 10 Codes: .......................................................................................................................................... 450 

Figure 5.175 - Artificial Pancreas by USPC Code ......................................................................................................................................................................................... 450 


Figure 5.176 – Artificial Pancreas - Text Clustering Analysis ...................................................................................................................................................................... 451 


Figure 5.177 - Artificial Pancreas by Source Jurisdiction ............................................................................................................................................................................ 452 

Top Patents ............................................................................................................................................................................................ 453 

Table 5.17 - Top Patents Identified in the Artificial Pancreas Group........................................................................................................................................................... 453 

US6175752: Abbott Laboratories .................................................................................................................................... 454 

Figure 5.178 – Representative Image in US6175752 ..................................................................................................................................................................................454 


US6122536: Johnson & Johnson ...................................................................................................................................... 456 

Figure 5.180 – Representative Image in US6122536 ................................................................................................................................................................................. 456 


6.0 PATENT ANALYSIS BY KEY COMPANIES ............................................................................................... 458 

Figure 6.1 – Number of Patents versus Revenue for Highlighted Companies ........................................................................................................................................... 459 

Litigation ............................................................................................................................................................................ 460 

Figure 6.2 – Litigation Analysis .................................................................................................................................................................................................................460 

6.1 Johnson & Johnson .............................................................................................................................................................. 461 

Johnson & Johnson Overall Patent Portfolio ...................................................................................................................461 


Figure 6.3 – Johnson & Johnson Overall Patent Portfolio by Priority Year ................................................................................................................................................ 461 


Figure 6.4 – Johnson & Johnson Overall Patent Portfolio by Published Year ............................................................................................................................................462 


Figure 6.5 – Johnson & Johnson Overall Patent Portfolio Source Jurisdiction ...........................................................................................................................................462 

Johnson & Johnson Patents Specific to This Study ......................................................................................................... 463 

Figure 6.6 – Johnson & Johnson Diabetes Patents by Technology Group .................................................................................................................................................463 


Figure 6.7 - Johnson & Johnson Diabetes Patents by Priority Year ............................................................................................................................................................464 

Publication Date by Year: .................................................................................................................................................. 464 

Figure 6.8 – Johnson & Johnson Diabetes Patents by Published Year.......................................................................................................................................................464 


Figure 6.9 – Johnson & Johnson Diabetes Patents by IPC Code .................................................................................................................................................................465 

USPC Analysis – Top 10 Codes: ...........................................................................................................................................................466 

Figure 6.10 – Johnson & Johnson Diabetes Patents by USPC Code ...........................................................................................................................................................466 


Figure 6.11 – Johnson & Johnson Diabetes Patents by Source Jurisdiction ...............................................................................................................................................467 

6.2 Abbott Laboratories............................................................................................................................................................468 

Abbott Overall Patent Portfolio ....................................................................................................................................... 468 


Figure 6.12 - Abbott Overall Patent Portfolio by Priority Year ....................................................................................................................................................................468 


Figure 6.13 – Abbott Overall Patent Portfolio by Published Year ..............................................................................................................................................................469 

May 2012 


xvii


xviii 



Figure 6.14 – Abbott Overall Patent Portfolio by Source Jurisdiction ........................................................................................................................................................469 

Abbott Patents Specific to This Study ...............................................................................................................................470 

Figure 6.15 – Abbott Diabetes Patents by Technology Group.................................................................................................................................................................... 470 


Figure 6.16 - Abbott Diabetes Patents by Priority Year .............................................................................................................................................................................. 471 

Publication Date by Year: .................................................................................................................................................................... 472 

Figure 6.17 – Abbott Diabetes Patents by Published Year ......................................................................................................................................................................... 472 

IPC Analysis– Top 10 Codes: ............................................................................................................................................................... 473 

Figure 6.18 – Abbott Diabetes Patents by IPC Code ................................................................................................................................................................................... 473 


Figure 6.19 – Abbott Diabetes Patents by USPC Code ................................................................................................................................................................................ 474 


Figure 6.20 – Abbott Diabetes Patents by Source Jurisdiction .................................................................................................................................................................. 475 

6.3 Roche Holding Ltd ................................................................................................................................................................ 476 

Roche Overall Patent Portfolio ..........................................................................................................................................476 


Figure 6.21 – Roche Overall Patent Portfolio by Priority Year ................................................................................................................................................................... 476 


Figure 6.22 - Roche Overall Patent Portfolio by Published Year................................................................................................................................................................. 477 


Figure 6.23 - Roche Overall Patent Portfolio by Source Jurisdiction........................................................................................................................................................... 477 

Roche Patents Specific to This Study ................................................................................................................................478 

Figure 6.24 – Roche Diabetes Patents by Technology Group ..................................................................................................................................................................... 478 


Figure 6.25 - Roche Diabetes Patents by Priority Year ............................................................................................................................................................................... 479 

Publication Date by Year: ....................................................................................................................................................................480 

Figure 6.26 - Roche Diabetes Patents by Published Year ...........................................................................................................................................................................480 


Figure 6.27 - Roche Diabetes Patents by IPC Code .....................................................................................................................................................................................481 


Figure 6.28 - Roche Diabetes Patents by USPC Code ..................................................................................................................................................................................482 


Figure 6.29 – Roche Diabetes Patents by Source Jurisdiction ....................................................................................................................................................................483 

6.4 Medtronic Inc .......................................................................................................................................................................484 

Medtronic Overall Patent Portfolio ................................................................................................................................. 484 


Figure 6.30 - Medtronic Overall Patent Portfolio by Priority Year ..............................................................................................................................................................484 


Figure 6.31 - Medtronic Overall Patent Portfolio by Published Year ..........................................................................................................................................................485 


Figure 6.32 – Medtronic Overall Patent Portfolio by Source Jurisdiction ...................................................................................................................................................485 

Medtronic Patents Specific to This Study ........................................................................................................................ 486 

Figure 6.33 – Medtronic Diabetes Patents by Technology Group ..............................................................................................................................................................486 


Figure 6.34 - Medtronic Diabetes Patents by Priority Year ........................................................................................................................................................................487 


Figure 6.35 - Medtronic Diabetes Patents by Published Year .....................................................................................................................................................................488 

IPC Analysis - Top 10 Codes: ................................................................................................................................................................ 489 

Figure 6.36 - Medtronic Diabetes Patents by IPC Code ...............................................................................................................................................................................489 

USPC Analysis- Top 10 Codes: ............................................................................................................................................................. 490 

Figure 6.37 - Medtronic Diabetes Patents by USPC Code ............................................................................................................................................................................490 


Figure 6.38 – Medtronic Diabetes Patents by Source Jurisdiction ............................................................................................................................................................. 491 

6.5 Becton, Dickinson and Co .................................................................................................................................................. 492 


May 2012


Becton, Dickinson and Co Overall Patent Portfolio .........................................................................................................492 


Figure 6.39 – Becton, Dickinson and Co Overall Patent Portfolio by Priority Year ..................................................................................................................................... 492 


Figure 6.40 – Becton, Dickinson and Co Overall Patent Portfolio by Published Year ................................................................................................................................. 493 


Figure 6.41 – Becton, Dickinson and Co Overall Patent Portfolio by Source Jurisdiction ........................................................................................................................... 493 

Becton, Dickinson and Co Patents Specific to This Study .............................................................................................. 494 

Figure 6.42 – Becton, Dickinson and Co Diabetes Patents by Technology Group ......................................................................................................................................494 


Figure 6.43 – Becton, Dickinson and Co Diabetes Patents by Priority Year................................................................................................................................................495 


Figure 6.44 – Becton, Dickinson and Co Diabetes Patents by Published Year ...........................................................................................................................................496 


Figure 6.45 – Becton, Dickinson and Co Diabetes Patents by IPC Code ...................................................................................................................................................... 497 


Figure 6.46 – Becton, Dickinson and Co Diabetes Patents by USPC Code ..................................................................................................................................................498 


Figure 6.47 – Becton, Dickinson and Co Diabetes Patents by Source Jurisdiction .....................................................................................................................................499 

6.6 Dexcom INC ..........................................................................................................................................................................500 

Dexcom Overall Patent Portfolio ..................................................................................................................................... 500 


Figure 6.48 - Dexcom Overall Patent Portfolio by Priority Year .................................................................................................................................................................500 


Figure 6.49 - Dexcom Overall Patent Portfolio by Published Year .............................................................................................................................................................. 501 


Figure 6.50 - Dexcom Overall Patent Portfolio by Source Jurisdiction ....................................................................................................................................................... 501 

Dexcom Patents Specific to This Study ............................................................................................................................ 502 

Figure 6.51 – Dexcom Diabetes Patents by Technology Group..................................................................................................................................................................502 


Figure 6.52 - Dexcom Diabetes Patents by Priority Year ............................................................................................................................................................................ 503 


Figure 6.53 – Dexcom Diabetes Patents by Published Year .......................................................................................................................................................................504 


Figure 6.54 – Dexcom Diabetes Patents by IPC Code .................................................................................................................................................................................505 


Figure 6.55 – Dexcom Diabetes Patents by USPC Code ..............................................................................................................................................................................506 


Figure 6.56 – Dexcom Diabetes Patents by Source Jurisdiction ................................................................................................................................................................. 507 

6.7 Novo Nordisk A/S .................................................................................................................................................................508 

Novo Nordisk Overall Patent Portfolio ............................................................................................................................ 508 


Figure 6.57 - Novo Nordisk Overall Patent Portfolio by Priority Year .........................................................................................................................................................508 


Figure 6.58 - Novo Nordisk Overall Patent Portfolio by Published Year .....................................................................................................................................................509 


Figure 6.59 - Novo Nordisk Overall Patent Portfolio by Source Jurisdiction ...............................................................................................................................................509 

Novo Nordisk Patents Specific to This Study....................................................................................................................510 

Figure 6.60 – Novo Nordisk Diabetes Patents by Technology Group ......................................................................................................................................................... 510 


Figure 6.61 - Novo Nordisk Diabetes Patents by Priority Year .................................................................................................................................................................... 511 

Publication Date by Year: .....................................................................................................................................................................512 

Figure 6.62 - Novo Nordisk Diabetes Patents by Published Year ................................................................................................................................................................ 512 

IPC Analysis – Top 10: Codes ................................................................................................................................................................513 

Figure 6.63 - Novo Nordisk Diabetes Patents by IPC Code .......................................................................................................................................................................... 513 

May 2012 


xix


xx 


USPC Analysis– Top 10 Codes: .............................................................................................................................................................514 

Figure 6.64 - Novo Nordisk Diabetes Patents by USPC Code ...................................................................................................................................................................... 514 


Figure 6.65 – Novo Nordisk Diabetes Patents by Source Jurisdiction ........................................................................................................................................................ 515 

6.8 Bayer AG ................................................................................................................................................................................ 516 

Bayer Overall Patent Portfolio ..........................................................................................................................................516 


Figure 6.66 - Bayer Overall Patent Portfolio by Priority Year ..................................................................................................................................................................... 516 


Figure 6.67 - Bayer Overall Patent Portfolio by Published Year ................................................................................................................................................................. 517 


Figure 6.68 - Bayer Overall Patent Portfolio by Source Jurisdiction ........................................................................................................................................................... 517 

Bayer Patents Specific to This Study .................................................................................................................................518 

Figure 6.69 – Bayer Diabetes Patents by Technology Group ..................................................................................................................................................................... 518 


Figure 6.70 - Bayer Diabetes Patents by Priority Year ................................................................................................................................................................................ 519 


Figure 6.71 - Bayer Diabetes Patents by Published Year ............................................................................................................................................................................ 520 


Figure 6.72 - Bayer Diabetes Patents by IPC Code ...................................................................................................................................................................................... 521 


Figure 6.73 - Bayer Diabetes Patents by USPC Code ................................................................................................................................................................................... 522 


Figure 6.74 – Bayer Diabetes Patents by Source Jurisdiction ..................................................................................................................................................................... 523 

6.9 Insulet Corporation ............................................................................................................................................................. 524 

Insulet Overall Patent Portfolio ........................................................................................................................................524 


Figure 6.75 - Insulet Overall Patent Portfolio by Priority Year .................................................................................................................................................................... 524 


Figure 6.76 – Insulet Overall Patent Portfolio by Published Year .............................................................................................................................................................. 525 


Figure 6.77 – Insulet Overall Patent Portfolio by Source Jurisdiction ........................................................................................................................................................ 525 

Insulet Patents Specific to This Study ...............................................................................................................................526 

Figure 6.78 – Insulet Diabetes Patents by Technology Group.................................................................................................................................................................... 526 


Figure 6.79 - Insulet Diabetes Patents by Priority Year .............................................................................................................................................................................. 527 


Figure 6.80 – Insulet Diabetes Patents by Published Year ......................................................................................................................................................................... 528 


Figure 6.81 – Insulet Diabetes Patents by IPC Code ................................................................................................................................................................................... 529 


Figure 6.82 – Insulet Diabetes Patents by USPC Code ................................................................................................................................................................................ 530 


Figure 6.83 – Insulet Diabetes Patents by Source Jurisdiction ................................................................................................................................................................... 531 

6.10 Nipro Diagnostic ................................................................................................................................................................ 532 

Nipro Overall Patent Portfolio ...........................................................................................................................................532 


Figure 6.84 – Nipro Overall Patent Portfolio by Priority Year .................................................................................................................................................................... 532 


Figure 6.85 – Nipro Overall Patent Portfolio by Published Year ................................................................................................................................................................ 533 


Figure 6.86 – Nipro Overall Patent Portfolio by Source Jurisdiction .......................................................................................................................................................... 533 

Nipro Patents Specific to This Study ................................................................................................................................ 534 

Figure 6.87 – Nipro Diabetes Patents by Technology Group ..................................................................................................................................................................... 534 



May 2012


Figure 6.88 - Nipro Diabetes Patents by Priority Year ................................................................................................................................................................................ 535 


Figure 6.89 – Nipro Diabetes Patents by Published Year ........................................................................................................................................................................... 536 


Figure 6.90 – Nipro Diabetes Patents by IPC Code ..................................................................................................................................................................................... 537 

USPC Codes – Top 10 Codes: ............................................................................................................................................................... 538 

Figure 6.91 – Nipro Diabetes Patents by USPC Code .................................................................................................................................................................................. 538 


Figure 6.92 – Nipro Diabetes Patents by Source Jurisdiction ..................................................................................................................................................................... 539 

6.11 Arkray Inc .............................................................................................................................................................................540 

Arkray Overall Patent Portfolio ........................................................................................................................................ 540 


Figure 6.93 – Arkray Overall Patent Portfolio by Priority Year ...................................................................................................................................................................540 


Figure 6.94 – Arkray Overall Patent Portfolio by Published Year .............................................................................................................................................................. 541 


Figure 6.95 – Arkray Overall Patent Portfolio by Source Jurisdiction ........................................................................................................................................................ 541 

Arkray Patents Specific to This Study .............................................................................................................................. 542 

Figure 6.96 – Arkray Diabetes Patents by Technology Group .................................................................................................................................................................... 542 


Figure 6.97 - Arkray Diabetes Patents by Priority Year .............................................................................................................................................................................. 543 


Figure 6.98 – Arkray Diabetes Patents by Published Year .........................................................................................................................................................................544 


Figure 6.99 – Arkray Diabetes Patents by IPC Code ...................................................................................................................................................................................545 


Figure 6.100 – Arkray Diabetes Patents by USPC Code ..............................................................................................................................................................................546 


Figure 6.101 – Arkray Diabetes Patents by Source Jurisdiction ................................................................................................................................................................. 547 

6.12 Sanofi – Aventis SA ............................................................................................................................................................548 

Sanofi-Aventis Overall Patent Portfolio .......................................................................................................................... 548 


Figure 6.102 - Sanofi-Aventis Overall Patent Portfolio by Priority Year .....................................................................................................................................................548 


Figure 6.103 - Sanofi-Aventis Overall Patent Portfolio by Published Year .................................................................................................................................................549 


Figure 6.104 - Sanofi-Aventis Overall Patent Portfolio by Source Jurisdiction ...........................................................................................................................................549 

Sanofi-Aventis Patents Specific to Diabetes Project ...................................................................................................... 550 

Figure 6.105 – Sanofi-Aventis Diabetes Patents by Technology Group ..................................................................................................................................................... 550 


Figure 6.106 - Sanofi-Aventis Diabetes Patents by Priority Year ............................................................................................................................................................... 551 


Figure 6.107 - Sanofi-Aventis Diabetes Patents by Published Year ............................................................................................................................................................ 552 


Figure 6.108 - Sanofi-Aventis Diabetes Patents by IPC Code ...................................................................................................................................................................... 553 

USPC Analysis– Top 10 Codes: ............................................................................................................................................................ 554 

Figure 6.109 - Sanofi-Aventis Diabetes Patents by USPC Code .................................................................................................................................................................. 554 


Figure 6.110 – Sanofi-Aventis Diabetes Patents by Source Jurisdiction..................................................................................................................................................... 555 

7.0 SUMMARY OF PATENT AND PRODUCT POSITIONS OF TOP DIABETES DEVICE COMPANIES ............. 556 

Table 7.1 – Table of Highlighted Companies and Technologies ................................................................................................................................................................. 556 

8.0 APPENDIX A - ASSUMPTIONS ............................................................................................................... 557 

Patent ..................................................................................................................................................................................557 

Current Assignee vs. Ultimate Parent ...............................................................................................................................557 

May 2012 


xxi


xxii 


9.0 APPENDIX B - PATENT STRENGTH......................................................................................................... 558 

10.0 APPENDIX C – TEXT CLUSTERING ....................................................................................................... 559 

GLOSSARY ...................................................................................................................................................... 560 


May 2012

Table of Contents - Espicom

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?